# Neoadjuvant Nab-Paclitaxel and S-1 in Resectable Pancreatic Cancer

> **NCT04808687** · PHASE2 · UNKNOWN · sponsor: **Tianjin Medical University Cancer Institute and Hospital** · enrollment: 72 (estimated)

## Conditions studied

- Pancreatic Neoplasms

## Interventions

- **DRUG:** Nab paclitaxel and S-1

## Key facts

- **NCT ID:** NCT04808687
- **Lead sponsor:** Tianjin Medical University Cancer Institute and Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-03
- **Primary completion:** 2023-02
- **Final completion:** 2024-02
- **Target enrollment:** 72 (ESTIMATED)
- **Last updated:** 2021-03-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04808687

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04808687, "Neoadjuvant Nab-Paclitaxel and S-1 in Resectable Pancreatic Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04808687. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*